EXPLORING THE POTENTIAL BIDIRECTIONAL RELATIONSHIP BETWEEN MIGRAINE AND DEPRESSION: A NARRATIVE REVIEW
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6378Keywords:
Migraine; Depression; Comorbidity; Bidirectional Association; Mendelian Randomisation; Shared MechanismsAbstract
Background: Migraine and depression frequently coexist, increasing disability and reducing quality of life. This review evaluated evidence on the direction and mechanisms of their relationship.
Methods: A critical narrative review used targeted searches of PubMed, Scopus, and Google Scholar for English-language publications from January 2016 to June 2026, supplemented by landmark studies. Evidence was synthesised qualitatively according to study design and its ability to inform association, temporal direction, or causality.
Results: Cross-sectional studies consistently associate migraine with depressive symptoms or reported depression. Prospective studies show temporal associations in both directions but do not establish causal bidirectionality. Mendelian randomisation has more often yielded estimates consistent with a potential influence of genetic liability to major depressive disorder on migraine risk than with the reverse pathway. Shared polygenic susceptibility and alterations in pain- and emotion-related neural systems, neurotransmitter and inflammatory signalling, stress regulation, sleep, anxiety, and functional impairment may contribute, but direct mechanistic evidence in clinically diagnosed comorbidity is limited. In a placebo-controlled trial, fremanezumab reduced monthly migraine days and depressive symptom scores in participants with a DSM-5-defined history of major depressive disorder and active symptoms; whether mood improvement was independent of reduced migraine burden remains uncertain.
Conclusions: Reciprocal assessment and coordinated management are reasonable, although their comparative effectiveness remains unproven. CGRP-targeted prevention may improve migraine burden and depressive symptoms in selected patients but should not replace targeted depression treatment. Research should use verified diagnoses, clarify mechanisms and causal direction, and test whether treating either disorder modifies the other.
References
Blumenfeld, A. M., Tepper, S. J., Robbins, L. D., Manack Adams, A., Buse, D. C., Orejudos, A., & Silberstein, S. D. (2019). Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety. Journal of Neurology, Neurosurgery & Psychiatry, 90(3), 353–360. https://doi.org/10.1136/jnnp-2018-319290
Brainstorm Consortium. (2018). Analysis of shared heritability in common disorders of the brain. Science, 360(6395), eaap8757. https://doi.org/10.1126/science.aap8757
Buse, D. C., Reed, M. L., Fanning, K. M., Bostic, R., Dodick, D. W., Schwedt, T. J., Munjal, S., Singh, P., & Lipton, R. B. (2020). Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: Results of the Migraine in America Symptoms and Treatment (MAST) study. The Journal of Headache and Pain, 21(1), 23. https://doi.org/10.1186/s10194-020-1084-y
Dodick, D. W., Silberstein, S. D., Bigal, M. E., Yeung, P. P., Goadsby, P. J., Blankenbiller, T., Grozinski-Wolff, M., Yang, R., Ma, Y., & Aycardi, E. (2018). Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial. JAMA, 319(19), 1999–2008. https://doi.org/10.1001/jama.2018.4853
Dresler, T., Caratozzolo, S., Guldolf, K., Huhn, J.-I., Loiacono, C., Niiberg-Pikksööt, T., Puma, M., Sforza, G., Tobia, A., Ornello, R., & Serafini, G. (2019). Understanding the nature of psychiatric comorbidity in migraine: A systematic review focused on interactions and treatment implications. The Journal of Headache and Pain, 20(1), 51. https://doi.org/10.1186/s10194-019-0988-x
Duan, S., Ren, Z., Xia, H., Wang, Z., Zheng, T., Li, G., Liu, L., & Liu, Z. (2023). Associations between anxiety, depression with migraine, and migraine-related burdens. Frontiers in Neurology, 14, 1090878. https://doi.org/10.3389/fneur.2023.1090878
Evans, R. W., Burch, R. C., Frishberg, B. M., Marmura, M. J., Mechtler, L. L., Silberstein, S. D., & Turner, D. P. (2020). Neuroimaging for migraine: The American Headache Society systematic review and evidence-based guideline. Headache: The Journal of Head and Face Pain, 60(2), 318–336. https://doi.org/10.1111/head.13720
Giri, S., Tronvik, E. A., & Hagen, K. (2022). The bidirectional temporal relationship between headache and affective disorders: Longitudinal data from the HUNT studies. The Journal of Headache and Pain, 23(1), 14. https://doi.org/10.1186/s10194-022-01388-x
Goadsby, P. J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J. H., Zhang, F., Sapra, S., Picard, H., Mikol, D. D., & Lenz, R. A. (2017). A controlled trial of erenumab for episodic migraine. New England Journal of Medicine, 377(22), 2123–2132. https://doi.org/10.1056/NEJMoa1705848
Hautakangas, H., Winsvold, B. S., Ruotsalainen, S. E., Bjornsdottir, G., Harder, A. V. E., Kogelman, L. J. A., Thomas, L. F., Noordam, R., Benner, C., Gormley, P., Artto, V., Banasik, K., Bjornsdottir, A., Boomsma, D. I., Brumpton, B. M., Burgdorf, K. S., Buring, J. E., Chalmer, M. A., de Boer, I., . . . Pirinen, M. (2022). Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. Nature Genetics, 54(2), 152–160. https://doi.org/10.1038/s41588-021-00990-0
Howard, D. M., Adams, M. J., Clarke, T.-K., Hafferty, J. D., Gibson, J., Shirali, M., Coleman, J. R. I., Hagenaars, S. P., Ward, J., Wigmore, E. M., Alloza, C., Shen, X., Barbu, M. C., Xu, E. Y., Whalley, H. C., Marioni, R. E., Porteous, D. J., Davies, G., Deary, I. J., . . . McIntosh, A. M. (2019). Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nature Neuroscience, 22(3), 343–352. https://doi.org/10.1038/s41593-018-0326-7
Hung, C.-I., Liu, C.-Y., Yang, C.-H., & Wang, S.-J. (2018). Migraine and greater pain symptoms at 10-year follow-up among patients with major depressive disorder. The Journal of Headache and Pain, 19(1), 56. https://doi.org/10.1186/s10194-018-0884-9
Johansson, E. W., Linde, M., Ohlis, A., Mattsson, M., Shaaban, A. N., Gustafsson, S., Holm, J., Dalman, C., & Agardh, E. E. (2026). Association of migraine with subsequent risk of depression or anxiety by small-area deprivation: National cohort study with sibling analysis. The Journal of Headache and Pain, 27(1), 57. https://doi.org/10.1186/s10194-026-02280-8
Knorr, U., Vinberg, M., Kessing, L. V., & Wetterslev, J. (2010). Salivary cortisol in depressed patients versus control persons: A systematic review and meta-analysis. Psychoneuroendocrinology, 35(9), 1275–1286. https://doi.org/10.1016/j.psyneuen.2010.04.001
Kuca, B., Silberstein, S. D., Wietecha, L., Berg, P. H., Dozier, G., & Lipton, R. B. (2018). Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology, 91(24), e2222–e2232. https://doi.org/10.1212/WNL.0000000000006641
Lampl, C., Thomas, H., Tassorelli, C., Katsarava, Z., Laínez, J. M., Lantéri-Minet, M., Rastenyte, D., Ruiz de la Torre, E., Stovner, L. J., Andrée, C., & Steiner, T. J. (2016). Headache, depression and anxiety: Associations in the Eurolight project. The Journal of Headache and Pain, 17(1), 59. https://doi.org/10.1186/s10194-016-0649-2
Li, W.-W., Zhang, J.-X., Wang, J., Chen, Y.-Q., Lai, S., & Qiu, Z.-K. (2024). Bidirectional two-sample Mendelian randomization analysis identifies causal associations between migraine and five psychiatric disorders. Frontiers in Neurology, 15, 1432966. https://doi.org/10.3389/fneur.2024.1432966
Li, Y., Luo, G., Zhou, L., Wang, X., Liu, H., Zhang, Y., & Yan, M. (2024). Mediators of the association between depression and migraine: A Mendelian randomization study. Frontiers in Genetics, 15, 1326817. https://doi.org/10.3389/fgene.2024.1326817
Lippi, G., & Mattiuzzi, C. (2017). Cortisol and migraine: A systematic literature review. Ağrı, 29(3), 95–99. https://doi.org/10.5505/agri.2017.25348
Lipton, R. B., Cohen, J. M., Galic, M., Seminerio, M. J., Yeung, P. P., Aycardi, E., Bigal, M. E., Bibeau, K., & Buse, D. C. (2021). Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache: The Journal of Head and Face Pain, 61(4), 662–672. https://doi.org/10.1111/head.14097
Lipton, R. B., Ramirez Campos, V., Roth-Ben Arie, Z., Galic, M., Mitsikostas, D., Tassorelli, C., Denysenko, L., & Cohen, J. M. (2025). Fremanezumab for the treatment of patients with migraine and comorbid major depressive disorder: The UNITE randomized clinical trial. JAMA Neurology, 82(6), 560–569. https://doi.org/10.1001/jamaneurol.2025.0806
Lv, X., Xu, B., Tang, X., Liu, S., Qian, J.-H., Guo, J., & Luo, J. (2023). The relationship between major depression and migraine: A bidirectional two-sample Mendelian randomization study. Frontiers in Neurology, 14, 1143060. https://doi.org/10.3389/fneur.2023.1143060
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023). The serotonin theory of depression: A systematic umbrella review of the evidence. Molecular Psychiatry, 28(8), 3243–3256. https://doi.org/10.1038/s41380-022-01661-0
Moon, H.-J., Seo, J.-G., & Park, S.-P. (2017). Perceived stress in patients with migraine: A case-control study. The Journal of Headache and Pain, 18(1), 73. https://doi.org/10.1186/s10194-017-0780-8
Osimo, E. F., Pillinger, T., Rodriguez, I. M., Khandaker, G. M., Pariante, C. M., & Howes, O. D. (2020). Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls. Brain, Behavior, and Immunity, 87, 901–909. https://doi.org/10.1016/j.bbi.2020.02.010
Ramsden, C. E., Zamora, D., Faurot, K. R., MacIntosh, B., Horowitz, M., Keyes, G. S., Yuan, Z.-X., Miller, V., Lynch, C., Honvoh, G., Park, J., Levy, R., Domenichiello, A. F., Johnston, A., Majchrzak-Hong, S., Hibbeln, J. R., Barrow, D. A., Loewke, J., Davis, J. M., . . . Mann, J. D. (2021). Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: Randomized controlled trial. BMJ, 374, n1448. https://doi.org/10.1136/bmj.n1448
Schmaal, L., Hibar, D. P., Sämann, P. G., Hall, G. B., Baune, B. T., Jahanshad, N., Cheung, J. W., van Erp, T. G. M., Bos, D., Ikram, M. A., Vernooij, M. W., Niessen, W. J., Tiemeier, H., Hofman, A., Wittfeld, K., Grabe, H. J., Janowitz, D., Bülow, R., Selonke, M., . . . Veltman, D. J. (2017). Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group. Molecular Psychiatry, 22(6), 900–909. https://doi.org/10.1038/mp.2016.60
Tiseo, C., Vacca, A., Felbush, A., Filimonova, T., Gai, A., Glazyrina, T., Hubalek, I. A., Marchenko, Y., Overeem, L. H., Piroso, S., Tkachev, A., Martelletti, P., & Sacco, S. (2020). Migraine and sleep disorders: A systematic review. The Journal of Headache and Pain, 21(1), 126. https://doi.org/10.1186/s10194-020-01192-5
Torres-Ferrús, M., Gallardo, V. J., Alpuente, A., Caronna, E., Giné-Ciprés, E., & Pozo-Rosich, P. (2024). Improvement of migraine depressive symptoms is not related to headache frequency: Exploring the impact of anti-CGRP therapies. Cephalalgia, 44(2), 03331024231222923. https://doi.org/10.1177/03331024231222923
Wells, R. E., O’Connell, N., Pierce, C. R., Estave, P., Penzien, D. B., Loder, E., Zeidan, F., & Houle, T. T. (2021). Effectiveness of mindfulness meditation vs headache education for adults with migraine: A randomized clinical trial. JAMA Internal Medicine, 181(3), 317–328. https://doi.org/10.1001/jamainternmed.2020.7090
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Mateusz Maciejewski, Alina Kozłowska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
